A 2024 review of BTK inhibitors in chronic lym... - CLL Support
A 2024 review of BTK inhibitors in chronic lymphocytic leukemia
You need to be a member of this community to see this post.
Read more about...
- Clinical trials
- Ibrutinib
- Rituximab
- Venetoclax
- Combination therapy
- Obinutuzumab
- FCR
- Chronic leukaemia
- Acalabrutinib
10 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase. Phase 1 trial results.
Rocbrutinib is a new drug offering hope to patients with what are known as gatekeeper mutations...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)
Pirtobrutinib is the first FDA approved non-covalent BTK inhibitor (BTKi) for the treatment of CLL....
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...
BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
Related Posts
BTK inhibitor challenges by Dr. Nicole Lamanna - Managing the cardiovascular risk of Bruton's Tyrosine Kinase Inhibitors in chronic lymphocytic leukemia
- Chronic lymphocytic leukemia treatment algorithm 2022
- Can Venetoclax/Obinituzimab reduce the risk of additional somatic mutations? - Not necessarily. The BTK inhibitors are excellent at....
- Efficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysis
